BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 873 filers reported holding BAXTER INTL INC in Q2 2016. The put-call ratio across all filers is 0.49 and the average weighting 0.4%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2018 | $4,895,000 | +12.4% | 66,292 | -1.0% | 1.15% | +10.2% |
Q1 2018 | $4,354,000 | -1.2% | 66,945 | -1.8% | 1.04% | +5.0% |
Q4 2017 | $4,409,000 | -0.7% | 68,206 | -3.6% | 1.00% | -0.8% |
Q3 2017 | $4,438,000 | +2.1% | 70,732 | -1.4% | 1.00% | +1.3% |
Q2 2017 | $4,345,000 | +16.5% | 71,766 | -0.3% | 0.99% | +21.6% |
Q1 2017 | $3,731,000 | +16.7% | 71,946 | -0.2% | 0.81% | +9.0% |
Q4 2016 | $3,197,000 | -7.0% | 72,096 | -0.2% | 0.75% | -8.3% |
Q3 2016 | $3,439,000 | +7.0% | 72,256 | +1.7% | 0.82% | +4.5% |
Q2 2016 | $3,213,000 | +8.7% | 71,056 | -1.3% | 0.78% | +3.7% |
Q1 2016 | $2,956,000 | +7.5% | 71,956 | -0.2% | 0.75% | +0.7% |
Q4 2015 | $2,750,000 | +15.5% | 72,081 | -0.6% | 0.75% | +14.6% |
Q3 2015 | $2,381,000 | -55.0% | 72,493 | -4.3% | 0.65% | -48.4% |
Q2 2015 | $5,296,000 | +2.1% | 75,732 | -0.0% | 1.26% | +6.0% |
Q1 2015 | $5,189,000 | -6.5% | 75,758 | +0.1% | 1.19% | -6.9% |
Q4 2014 | $5,549,000 | +1.2% | 75,708 | -0.9% | 1.28% | +0.3% |
Q3 2014 | $5,484,000 | -0.8% | 76,408 | -0.0% | 1.28% | +2.7% |
Q2 2014 | $5,527,000 | -2.8% | 76,443 | -1.1% | 1.24% | -8.3% |
Q1 2014 | $5,686,000 | +6.9% | 77,270 | +1.1% | 1.36% | +6.4% |
Q4 2013 | $5,318,000 | +8.8% | 76,456 | +2.8% | 1.28% | -0.4% |
Q3 2013 | $4,886,000 | -5.2% | 74,386 | +0.0% | 1.28% | -10.6% |
Q2 2013 | $5,152,000 | – | 74,377 | – | 1.43% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Point | 36,000,000 | $2,658,240,000 | 18.52% |
SECTOR GAMMA AS | 721,058 | $53,243,000 | 8.85% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 2,747,061 | $202,843,000 | 5.38% |
Veritas Asset Management LLP | 8,852,005 | $653,632,000 | 5.36% |
Knowledge Leaders Capital, LLC | 79,384 | $5,862,000 | 4.39% |
HealthCor Management, L.P. | 1,800,000 | $132,912,000 | 4.22% |
Progressive Investment Management Corp | 79,282 | $5,854,000 | 3.78% |
13D Management LLC | 200,318 | $14,791,000 | 3.77% |
ARGENT CAPITAL MANAGEMENT LLC | 1,288,236 | $95,123,000 | 3.42% |
Chiron Investment Management, LLC | 612,787 | $45,248,000 | 3.12% |